

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number  
**WO 00/50568 A3**

- (51) International Patent Classification<sup>7</sup>: C12N 5/06
- (21) International Application Number: PCT/GB00/00636
- (22) International Filing Date: 23 February 2000 (23.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
9904281.4 24 February 1999 (24.02.1999) GB
- (71) Applicant (for all designated States except US): RENEURON LIMITED [GB/GB]; 12 St. James's Square, London SW1Y 4RB (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): PRICE, Jack [GB/GB]; ReNeuron Limited, Europoint Centre, 5-11 Lavington Street, London SE1 0NZ (GB).
- (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- (88) Date of publication of the international search report:  
7 December 2000
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSPLANTATION OF HAEMATOPOIETIC CELLS

(57) Abstract: Transplantation of haematopoietic stem cells is proposed for the treatment of a damaged brain. Intracerebral transplantation of haematopoietic stem cells may repair function and may be suitable for the treatment of Alzheimer's disease, Parkinson's disease and Creutzfeld-Jacob disease.

WO 00/50568 A3

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                     |    |                       |    |                          |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AL | Albania                  | ES | Spain               | LS | Lesotho               | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland             | LT | Lithuania             | SK | Slovakia                 |
| AT | Austria                  | FR | France              | LU | Luxembourg            | SN | Senegal                  |
| AU | Australia                | GA | Gabon               | LV | Latvia                | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom      | MC | Monaco                | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia             | MD | Republic of Moldova   | TG | Togo                     |
| BB | Barbados                 | GH | Ghana               | MG | Madagascar            | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea              | MK | The former Yugoslav   | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece              |    | Republic of Macedonia | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary             | ML | Mali                  | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland             | MN | Mongolia              | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel              | MR | Mauritania            | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland             | MW | Malawi                | US | United States of America |
| CA | Canada                   | IT | Italy               | MX | Mexico                | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan               | NE | Niger                 | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya               | NL | Netherlands           | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan          | NO | Norway                | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's | NZ | New Zealand           |    |                          |
| CM | Cameroon                 |    | Republic of Korea   | PL | Poland                |    |                          |
| CN | China                    | KR | Republic of Korea   | PT | Portugal              |    |                          |
| CU | Cuba                     | KZ | Kazakhstan          | RO | Romania               |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia         | RU | Russian Federation    |    |                          |
| DE | Germany                  | LI | Liechtenstein       | SD | Sudan                 |    |                          |
| DK | Denmark                  | LK | Sri Lanka           | SE | Sweden                |    |                          |
| EE | Estonia                  | LR | Liberia             | SG | Singapore             |    |                          |

## TRANSPLANTATION OF HAEMATOPOIETIC CELLS

### Field of the Invention

The present invention relates to the correction of sensory, motor and/or cognitive deficits by the intracerebral transplantation of cells, and to cells and medicaments therefor.

### Background to the Invention

Sensory, motor and/or cognitive deficits are caused by many diseases and may also be caused when the brain undergoes trauma. For example, motor dysfunction is one symptom of Parkinson's disease. As yet, in most cases, there is no satisfactory treatment available.

Bjornson *et al*, Science (1999) 283:534-537, describes the ability of neural stem cells to produce a variety of blood cell types, including myeloid, lymphoid and haematopoietic cells. It is believed that the neural stem cells contain appropriate mechanisms required to express otherwise silent genetic information to respond to signals that normally stimulate blood stem cells. The experiment suggests that the adult blood system contains powerful signals that "activate" the neural stem cells.

Haematopoietic cells are the progenitor cells for all of the blood cells, including leukocytes and erythrocytes. The transplantation of such cells has been proposed, for example, in WO-A-92/11355, in connection with haematopoietic disorders, including sickle cell anaemia and haemophilia. Methods for culturing and genetically altering haematopoietic stem cells are disclosed in WO-A-92/11355 and WO-A-93/18137.

### Summary of the Invention

The present invention is based in part on the observation that, when transplanted into a damaged or diseased brain, haematopoietic stem cells appear to respond to signals from the damaged or diseased brain by taking up a phenotype that is able to replace or compensate for functional deficits to which the damage or disease otherwise leads.

For use in the present invention, the haematopoietic stem cells should be capable of differentiating into cells appropriate to repair or compensate for

the damage or disease in the target area of the brain. It will be appreciated that cells for transplantation need not be capable of differentiation into all types or phenotypes of neural cells.

The treatment may be carried out on any mammal but the present invention is especially concerned with the treatment of humans, especially treatment with human cells, and with human cells and cell lines.

The cells of the present invention are capable of correcting a sensory, motor and/or cognitive deficit when implanted into a damaged part of the human brain. The term "damage" used herein includes reduction or loss of function.

The term also includes cell loss. Damage may be caused by any of a variety of means including physical trauma, hypoxia (lack of oxygen), chemical agents, for example, damage may be caused by drug abuse, and disease. The following diseases and pathological conditions are examples of diseases or conditions which result in sensory, motor and/or cognitive deficits which may be treated in accordance with the present invention: traumatic brain injury, stroke, perinatal ischaemia, including cerebral palsy, Alzheimer's, Pick's and related dementing neurodegenerative diseases, multi-infarct dementia, Parkinson's and Parkinson's type diseases, Huntington's disease, Korsakoff's disease and Creutzfeld-Jacob disease. Amnesia, particularly following transitory global ischaemia such as after cardiac arrest or coronary bypass surgery, may also be treated in accordance with the present invention.

The cells may also be administered to sites distant from the actual site of damage, for example, the cells may be administered to the contra-lateral region from that exhibiting damage.

The present invention provides for the use of haematopoietic stem cells, optionally in isolated form, in the manufacture of a medicament for the treatment of a sensory, motor and/or cognitive deficit. The medicament to be administered comprises haematopoietic stem cells.

The present invention further provides for the use of conditionally immortal, haematopoietic stem cells in the manufacture of a medicament for the

treatment of a sensory, motor and/or cognitive deficit. The medicament to be administered comprises conditionally immortal, haematopoietic stem cells.

The conditionally immortal cells according to, and used in, the present invention may be from clonal cell lines or may be of mixed population. Cells  
5 from clonal cell lines may be preferred. Cells from a single cell line may be used or a mixture of cells from two or more cell lines may be used.

The invention further provides a pharmaceutical preparation comprising cells according to the invention and a pharmaceutically acceptable carrier.

#### Description of the Invention

10 The present invention is based on the realisation that when haematopoietic stem cells are implanted into a damaged brain, the cells surprisingly differentiate into a form of cell that is capable of repairing the damage and improve function. The phenotype of the differentiated cells may be the same as the phenotype of the damaged or lost cells, however, the  
15 differentiated cells may be of a different phenotype, or of a number of phenotypes. In any case, the cells take up a phenotype that is capable of functionally integrating and compensating for the damaged or lost cells. That is assisted by the propensity, that we have discovered, of the cells to migrate to, and seek out, damaged tissue.

20 The use of stem cells means that with one clonal cell line it is possible to repair damage in a number of different areas of the brain. It also means that if more than one particular cell type is required to repair damage in a given area then a single cell line will be capable of differentiating into the different types of cells required.

25 Conditionally immortal cells are cells which are immortal under certain permissive conditions but are not immortal under nonpermissive conditions. In the present case this means that by conditionally immortalising the stem cells and maintaining them under permissive conditions the development of the stem cells may be arrested at a chosen stage and they may be propagated for long  
30 periods. Use of conditionally immortalisation allows the development of clonal lines which are readily expandable in vitro. If the conditions under which the

cells are maintained are switched to nonpermissive conditions, the development of the cells is allowed to continue. If the correct conditions are provided the cells will continue to develop and will differentiate.

5       Immortalised cells are usually prepared by the transduction of an oncogene into cells. There is therefore a risk of tumour formation in the long term, so such cells are not preferred for use in the present invention.

10       Conditionally immortal cells have the advantages of immortal cells in that they are "frozen" in the desired stage of development, are easily maintained and multiply well when under permissive conditions but they may be used in transplants as long as the environment into which they are transplanted has nonpermissive conditions. In the case of the cells of the present invention the gene used to confer conditional immortality should be chosen so that the conditions present in the brain will correspond to nonpermissive conditions.

15       An example of a suitable conditionally immortal oncogene is that which expresses the non-DNA binding, temperature-sensitive T antigen; a description of which may be found in US-A-5688692 or WO-A-97/10329.

      If non-immortal cells are used then these may be maintained *in vitro* in culture media with the addition of growth factors as disclosed in WO-A-92/11355 and WO-A-93/18137.

20       The gene which is used to confer conditional immortality may be incorporated into cells after extraction from the bone marrow of an animal.

      The cells used in the treatment of humans should preferably be derived from human cells to reduce problems with immune rejection. This requires the extraction of cells from the bone marrow of a human.

25       However, the cells do not necessarily have to be conditionally immortal, and may be obtained directly from the patient to be treated.

      To treat a patient it is generally of assistance to know where damage has occurred in the brain. Once the existence of damage has been established, whether it be in one isolated area or in several areas, treatment by implantation of cells into the damaged area may be carried out. In many cases, however, the  
30       location and/or type of damaged tissue may be unknown or only poorly

characterised. For example, neurodegenerative diseases may lead to widespread damage to different types of cells. Treatment of such damage is still possible and is assisted by the ability of the haematopoietic stem cells to migrate extensively once transplanted and to seek out damaged tissue. The stem cells may be transplanted at a single site, or preferably at multiple sites, and may be able to migrate to the site(s) of damage and, once there, differentiate in response to the local microenvironment, into the necessary phenotype or phenotypes to improve or restore function.

After treatment the progress of the patient may be monitored using sensory, motor and/or cognitive tests and/or, if desired, tests which monitor brain activity in selected areas of the brain. For example, tests for cognitive function may be performed before and after transplantation.

Preferably, treatment will substantially correct a sensory, motor and/or cognitive deficit (behavioural and/or psychological deficits). However, that may not always be possible. Treatment according to the present invention and with the cells, medicaments and pharmaceutical preparations of the invention, may lead to improvement in function without complete correction. Such improvement will be worthwhile and of value.

The number of cells to be used will vary depending on the nature and extent of the damaged tissue. Typically, the number of cells used in transplantation will be in the range of about one hundred thousand to several million. Treatment need not be restricted to a single transplant. Additional transplants may be carried out to further improve function.

To study the transplantation in animal models the tests described in Hodges, *et al*, Pharmacology, Biochemistry and Behaviour (1997) 56(4):763-780 may be used. One test utilises rats in which the technique for four-vessel occlusion (4 VO), simulating human heart attack, causes relatively circumscribed and specific damage to the CA 1 pyramidal cells of the dorsal hippocampus, along with a cognitive deficit manifest as difficulty in locating a submerged and invisible platform in a swimming pool. This provides a model of cognitive dysfunction occurring as a consequence of a common form of brain

damage, i.e., transient loss of blood supply to the brain, for example, as may occur during cardiac arrest.

Methods for transplantation of cells into humans and animals are known to those in the art and are described in the literature in the art. The term  
5 "transplantation" used herein includes the transplantation of cells which have been grown *in vitro*, and may have been genetically modified, as well as the transplantation of material extracted from another organism. Cells may be transplanted by implantation by means of microsyringe infusion of a known quantity of cells in the target area where they would normally disperse around  
10 the injection site. They may also be implanted into ventricular spaces in the brain. If implanted into the neonate then they may disperse throughout the entire brain.

The phrase "intracerebral transplantation" used herein includes transplantation into any portion of the brain. Transplantation is not restricted to  
15 the front and larger part of the brain.

The utility of the present invention has now been reported independently in Chopp *et al*, Society for Neuroscience (1999), Vol. 25, Abstract No. 528.2. This Abstract was published after the priority date of the present Application and details the intracerebral transplantation of haematopoietic stem cells in  
20 mice.

As detailed in the Abstract, adult mice were subjected to middle cerebral artery occlusion (MCAo), and cultured haematopoietic stem cells (infused with growth factor) were transplanted into the ischaemic striatum (4 days after MCAo). Cell type specific markers were used for identification of the donor  
25 cells on transplantation. The results showed that donor cells survived transplantation and were morphologically detectable in the ischaemic striatum, exhibiting the phenotype of neuronal and astrocyte cells.

Suitable excipients, diluents and carriers will be apparent to the skilled person and formulations suitable for intracerebral transplantation will also be  
30 apparent.



The stem cells of the present invention may be genetically transformed to express a heterologous gene product. In particular, a therapeutic gene product that exerts its effect at the site of damage. Examples of suitable gene products are disclosed in US-A-5958767.

CLAIMS

1. Use of a haematopoietic stem cell in the manufacture of a medicament for the treatment of a sensory, motor and/or cognitive deficit.
2. Use according to claim 1, for intracerebral transplantation into a  
5 damaged brain.
3. Use according to claim 1 or claim 2, wherein the treatment is for Alzheimer's disease, Parkinson's disease, Korsakoff's disease or Creutzfeld-Jacob disease.
4. Use according to any preceding claim, wherein the haematopoietic stem  
10 cell is conditionally immortal.
5. Use according to claim 4, wherein the cell comprises a temperature sensitive oncogene which is not expressed at a temperature above 35°C.
6. Use according to claim 5, wherein the oncogene expresses the SV40 T-antigen.
- 15 7. Use according to any preceding claim, wherein the haematopoietic stem cell is genetically transformed to express a therapeutic heterologous gene product.
8. A method for treating a sensory, motor and/or cognitive deficit, comprising the intracerebral transplantation of haematopoietic stem cells.
- 20 9. A method according to claim 8, wherein the cells are as defined in any of claims 4 to 7.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/00636

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N5/06

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                            | Relevant to claim No. |
|------------|---|-----------------------|
| X          | US 5 817 773 A (WILSON ELAINE LYNETTE ET AL) 6 October 1998 (1998-10-06)                                      | 1-3                   |
| Y          | column 6, line 24 - line 37; claims 1,21-24   | 4-7                   |
|            | column 13, line 33 -column 14, line 20  |                       |
| Y          | WO 97 10329 A (INST OF PSYCHIATRY ;SINDEN JOHN (GB); GRAY JEFFREY ALAN (GB); HODG) 20 March 1997 (1997-03-20) | 4-6                   |
| A          | page 1, paragraph 1 - paragraph 4; claim 1  | 1                     |
|            | page 8, paragraph 4; claim 5  |                       |
|            | page 2, paragraph 1   |                       |
|            | page 2, paragraph 7 - paragraph 8   |                       |
|            | page 5, paragraph 2   |                       |
|            | ---<br>-/--   |                       |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 August 2000

Date of mailing of the international search report

21/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Charles, D

# INTERNATIONAL SEARCH REPORT

Inter      al Application No  
PCT/GB 00/00636

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |                       |
|--|--|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
| Y  | J.A. ALLAY ET AL.: "LACZ AND INTERLEUKIN-3 EXPRESSION IN VIVO AFTER RETROVIRAL TRANSDUCTION OF MARROW-DERIVED HUMAN OSTEOGENIC MESENCHYMAL PROGENITORS" HUMAN GENE THERAPY, vol. 8, no. 12, 10 August 1997 (1997-08-10), pages 1417-1427, XP002145778 abstract   | 7                     |
| X  | WO 93 18137 A (SYSTEMIX INC)<br>16 September 1993 (1993-09-16)<br>cited in the application<br>page 1, line 3 - line 4<br>page 4, line 16 - line 20<br>page 13, line 3 - line 18  | 1-3                   |
| X,P  | M. CHOPP ET AL.: "ADULT BONE MARROW TRANSPLANTATION FOR TREATMENT OF STROKE IN ADULT MICE" SOCIETY FOR NEUROSCIENCE, vol. 25, 1999, page 528.2 XP000900788 cited in the application abstract   | 1,2,8                 |
| A  | WO 98 07841 A (UNIV MASSACHUSETTS)<br>26 February 1998 (1998-02-26)<br>page 1, line 4 - line 18; claims 16-30<br>page 5, line 26 -page 6, line 10<br>page 8, line 2 - line 14<br>page 12, line 6 - line 16<br>page 20, line 19 -page 21, line 11<br>page 21, line 27 -page 22, line 19   | 1-9                   |
| A  | HODGES, HELEN (1) ET AL: "Cognitive deficits induced by global cerebral ischaemia: Prospects for transplant therapy." PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, (1997) VOL. 56, NO. 4, PP. 763-780., vol. 56, no. 4, 1997, pages 763-780, XP000857876 cited in the application<br>page 771, column 1, paragraph 1 -page 776, column 1, paragraph 1 | 1-9                   |
| A  | WO 92 11355 A (UNIV MICHIGAN)<br>9 July 1992 (1992-07-09)<br>cited in the application<br>page 1, line 10 - line 13; claim 1<br>page 11, line 24 -page 12, line 18<br>page 14, line 16 - line 19  | 1-3                   |

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 00 00636

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 8,9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Although claims 8 and 9 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/00636

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| US 5817773 A                              | 06-10-1998          | US 5612211 A               | 18-03-1997          |
|   |                     | AT 164076 T                | 15-04-1998          |
|   |                     | DE 69129113 D              | 23-04-1998          |
|   |                     | DE 69129113 T              | 15-10-1998          |
|   |                     | EP 0535148 A               | 07-04-1993          |
|   |                     | JP 5509096 T               | 16-12-1993          |
|   |                     | WO 9118620 A               | 12-12-1991          |
| WO 9710329 A                              | 20-03-1997          | AU 711563 B                | 14-10-1999          |
|   |                     | AU 6937596 A               | 01-04-1997          |
|   |                     | CA 2231436 A               | 20-03-1997          |
|   |                     | CN 1193345 A               | 16-09-1998          |
|   |                     | CZ 9800558 A               | 17-06-1998          |
|   |                     | EP 0850298 A               | 01-07-1998          |
|   |                     | HU 9802091 A               | 28-12-1998          |
|   |                     | JP 11513242 T              | 16-11-1999          |
|   |                     | NO 981072 A                | 12-05-1998          |
|   |                     | PL 325646 A                | 03-08-1998          |
|   |                     | SK 30698 A                 | 11-01-1999          |
| WO 9318137 A                              | 16-09-1993          | AU 680406 B                | 31-07-1997          |
|   |                     | AU 3783993 A               | 05-10-1993          |
|   |                     | AU 4369097 A               | 12-02-1998          |
|   |                     | CA 2131368 A               | 16-09-1993          |
|   |                     | EP 0631618 A               | 04-01-1995          |
|   |                     | JP 7504331 T               | 18-05-1995          |
| WO 9807841 A                              | 26-02-1998          | AU 4044397 A               | 06-03-1998          |
|   |                     | BR 9711204 A               | 17-08-1999          |
|   |                     | CN 1230989 A               | 06-10-1999          |
|   |                     | EP 0934403 A               | 11-08-1999          |
| WO 9211355 A                              | 09-07-1992          | US 5399493 A               | 21-03-1995          |
|   |                     | AU 687674 B                | 26-02-1998          |
|   |                     | AU 5059296 A               | 11-07-1996          |
|   |                     | AU 665525 B                | 11-01-1996          |
|   |                     | AU 9175091 A               | 22-07-1992          |
|   |                     | CA 2100268 A               | 18-06-1992          |
|   |                     | EP 0575350 A               | 29-12-1993          |
|   |                     | JP 11221074 A              | 17-08-1999          |
|   |                     | JP 6505151 T               | 16-06-1994          |
|   |                     | US 5437994 A               | 01-08-1995          |
|   |                     | US 5635386 A               | 03-06-1997          |
|   |                     | US 5605822 A               | 25-02-1997          |
|   |                     | US 5670147 A               | 23-09-1997          |
|   |                     | US 5670351 A               | 23-09-1997          |
|   |                     | US 5646043 A               | 08-07-1997          |